Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized study of tanezumab with or without NSAIDs versus NSAIDs in osteoarthritis of the knee or hip
2008-004815-37Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tanezumab in knee osteoarthritis (OA) and hip osteoarthritis (4 arms), sponsored by Pfizer. Primary endpoints: Co-primary analgesic efficacy endpoints and Long-term safety endpoints. Started Dec 2008; status: completed.
02
Drugs
tanezumab
03
Conditions
knee osteoarthritis (OA)hip osteoarthritis
Beyond the preview
Go deeper on 2008-004815-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004815-37.